SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation

An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation


  • Org Study ID: NCI-2015-00121
  • Secondary ID: NCI-2015-00121,2000021268,1505015958,9767,9767,UM1CA186689
  • NCT ID: NCT03047213
  • NCT Alias: NCT03108261
  • Sponsor: National Cancer Institute (NCI) - NIH
  • Source: National Cancer Institute (NCI)

Brief Summary

This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and/or TSC2 mutations (changes in deoxyribonucleic acid [DNA]). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description


PRIMARY OBJECTIVES:

I. To determine the overall response rate (ORR) defined as complete response (CR) and partial
response (PR) in patients with locally advanced or metastatic transitional cell carcinoma
(TCC) harboring a TSC1 mutation.

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of sapanisertib (MLN0128) (TAK-228) in patients
with locally advanced or metastatic TCC harboring a TSC1 or TSC2 mutation.

II. To evaluate progression free survival (PFS) and overall survival (OS).

TERTIARY OBJECTIVES:

I. To determine the ORR in patients with locally advanced or metastatic TCC harboring a TSC2
mutation.

II. To evaluate toxicity, PFS, and OS in TSC2 mutation patients.

OUTLINE:

Patients receive sapanisertib orally (PO) once daily (QD) on days 1-28. Courses repeat every
28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks and every 6 months
thereafter.

Overal Status Start Date Phase Study Type
Recruiting December 1, 2016 Phase 2 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Overall response rate (TSC1 patients)

Primary Outcome 1 - Time Frame: Up to 4 weeks after last dose of study treatment

Condition:

  • Metastatic Transitional Cell Carcinoma
  • Metastatic Urothelial Carcinoma
  • Recurrent Bladder Carcinoma
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage IV Bladder Urothelial Carcinoma AJCC v7
  • TSC1 Gene Mutation
  • TSC2 Gene Mutation

Eligibility

Criteria:
Inclusion Criteria:

- Patients must have measurable disease as defined by Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1

- Must have a histologically confirmed transitional cell carcinoma (TCC, also known as
> urothelial carcinoma), locally advanced or metastatic

- Patient must have TCCs tumors harboring a TSC1 or TSC2 mutation identified by a
Clinical Laboratory Improvement Amendments (CLIA) certified laboratory

- Unless the pre-screening was performed at Yale Clinical Molecular Pathology Lab
(YCMPL), patients must have TCC tumor tissue available for submission in a form of at
least 10 unstained slides or formalin-fixed paraffin-embedded (FFPE) block (FFPE block
highly recommended and preferred) along with a buccal swab; if the number of slides is
less than 10, a biopsy should be considered; if a biopsy is deemed unsafe, the case
may be discussed with the study principal investigator (PI) and approval must be given
for eligibility

- Patient must have developed disease progression during or following treatment with at
least one platinum-containing regimen (e.g., gemcitabine/cisplatin [GC],
methotrexate-vinblastine-doxorubicin-cisplatin [MVAC], carboplatin, gemcitabine
[CarboGem]) for inoperable locally advanced or metastatic urothelial carcinoma or
disease recurrence, or must be unfit or ineligible for cisplatin-based chemotherapy;
there is no restriction on the number of prior lines of chemotherapeutics agents
received

- Patients who progressed within 12 months of treatment with a platinum-containing
neoadjuvant or adjuvant regimen are considered second-line patients; therefore,
these patients may be also eligible

- Patients who are unfit or ineligible for cisplatin-based chemotherapy as defined
by any one of the following criteria are eligible for this trial:

- Eastern Cooperative Oncology Group (ECOG) performance score of 2

- Creatinine clearance < 60 mL/min

- A hearing loss (measured by audiometry) of 25 dB at two contiguous
frequencies

- Grade >= 2 peripheral neuropathy

- ECOG performance status =< 2 (Karnofsky >= 60 %)

- Life expectancy of greater than 12 weeks

- Hemoglobin >= 9 g/dL

- Fasting serum glucose =< 130 mg/dL

- Glycosylated hemoglobin measurement (HbA1c) < 7.0%

- Fasting triglycerides =< 300 mg/dL

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin within normal institutional limits

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 × institutional upper limit of normal (ULN) and =< 5 ULN if liver metastases
are present

- Creatinine =< 1.5 x upper normal institutional limits (UNL) OR creatinine clearance >=
40 mL/min based either on Cockcroft-Gault estimate or based on urine collection (12 or
24 hour)

- Patients with controlled diabetes are allowed on study; controlled diabetes is defined
as fasting blood sugar (FBS) = 130 mg/dL or less, and patients whose FBS can be
brought in this range with medical therapy are eligible for trial inclusion

- Women of childbearing age should avoid becoming pregnant while taking any mTOR
inhibitor including MLN0128 (TAK-228)

- Female patients must:

- Be postmenopausal for at least 1 year before the screening visit, OR

- Be surgically sterile, OR

- If they are of childbearing potential, agree to practice 1 highly effective
method of contraception and 1 additional effective (barrier) method, at the
same time, from the time of signing the informed consent through 90 days (or
longer, as mandated by local labeling [e.g., United States product insert
[USPI], summary of product characteristics [SmPC], etc.;]) after the last
dose of study drug, OR

- Agree to practice true abstinence, when this is in line with the preferred
and usual lifestyle of the patient; NOTE: periodic abstinence [e.g.,
calendar, ovulation, symptothermal, postovulation methods], withdrawal,
spermicides only, and lactational amenorrhea are not acceptable methods of
contraception; female and male condoms should not be used together

- Male patients, even if surgically sterilized (i.e., status postvasectomy), must:

- Agree to practice highly effective barrier contraception during the entire
study treatment period and through 120 days after the last dose of study
drug, OR

- Agree to practice true abstinence, when this is in line with the preferred
and usual lifestyle of the patient (NOTE: periodic abstinence [e.g.,
calendar, ovulation, symptothermal, postovulation methods for the female
partner], withdrawal, spermicides only, and lactational amenorrhea are not
acceptable methods of contraception; female and male condoms should not be
used together)

- AND agree not to donate sperm during the course of this study or within 120
days after receiving their last dose of study drug

- Ability to swallow oral medications

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had chemotherapy, immunotherapy, or investigational therapy, within
4 weeks (6 weeks for nitrosoureas or mitomycin C), or palliative radiotherapy within 2
weeks prior to the first dose of the study drug

- Patients who have not recovered from adverse events due to prior anti-cancer therapy
to grade 1 or baseline; patients with stable, controlled grade 2 adverse events (AEs)
such as peripheral neuropathy, hypothyroidism, hypertension, adrenal insufficiency or
alopecia are allowed after discussing with the PI

- Patients with known symptomatic, untreated central nervous system (including brain,
spinal cord)

- Patients who have a history of brain/central nervous system (CNS) metastasis are
eligible for the study provided that all the following criteria are met:

- Brain/CNS metastases which have been treated

- No evidence of disease progression for >= 3 months before the first dose of
study drug

- No hemorrhage after treatment

- Off-treatment with dexamethasone for 4 weeks before administration of the
first dose of TAK-228

- No ongoing requirement for dexamethasone or anti-epileptic drugs

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to MLN0128 (TAK-228)

- Subjects who are on systemic corticosteroids (intravenous (IV) or oral steroids,
excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for
treated brain metastasis

- Subjects taking strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4,
CYP2C19 or CYP2C9 within 1 week preceding the first dose of MLN0128 (TAK-228); if a
subject requires treatment with strong inhibitors and/or inducers of CYP3A4, CYP2C19
and/or CYP2C9, alternative treatment must be considered; if no alternative is
available, one such medication may be allowed after discussing with the study
principle investigator

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia (excluding rate controlled atrial fibrillation/flutter), or psychiatric
illness/social situations that would limit compliance with study requirements

- Pregnant and breastfeeding women are excluded from this study; breastfeeding should be
discontinued if the mother is treated with MLN0128 (TAK-228)

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible; however, HIV patients treated with regimens that have low
cytochrome P450 (CYP450) inhibition may be allowed as long as the patient's general
health and cluster of differentiation (CD)4 counts are within acceptable levels

- Patients with baseline prolongation of the rate-corrected QT interval (QTc) (e.g.,
repeated demonstration of QTc interval > 480 milliseconds, or history of congenital
long QT syndrome, or torsades de pointes)

- Patients with untreated or active hepatitis B or C infection

- Significant active cardiovascular or pulmonary disease at the time of study entry,
including

- Uncontrolled high blood pressure (i.e., systolic blood pressure > 180 mm Hg,
diastolic blood pressure > 95 mm Hg)

- Pulmonary hypertension

- Uncontrolled asthma or oxygen (O2) saturation < 90% by ABG (arterial blood gas)
analysis or pulse oximetry on room air

- Significant valvular disease; severe regurgitation or stenosis by imaging
independent of symptom control with medical intervention, or history of valve
replacement

- Medically significant (symptomatic) bradycardia

- Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI
disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228)

- Concomitant administration of any proton pump inhibitor (PPI) is not permitted during
the study; patients receiving PPI therapy before enrollment must stop using the PPI
for 7 days before their first dose of study drugs

- History of any of the following within the last 6 months prior to study entry:

- Ischemic myocardial event, including angina requiring therapy and artery
revascularization procedures

- Ischemic cerebrovascular event, including transient ischemic attack (TIA) and
artery revascularization procedures

- Requirement for inotropic support (excluding digoxin) or serious (uncontrolled)
cardiac arrhythmia (including atrial flutter/fibrillation, ventricular
fibrillation or ventricular tachycardia)

- Pulmonary embolism

- New York Heart Association (NYHA) class III or IV heart failure

- Placement of a pacemaker for control of rhythm

- Subjects who have initiated treatment with bisphosphonates less than 30 days prior to
the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only
allowed if the bisphosphonate was initiated at least 30 days prior to the first
administration of MLN0128 (TAK-228)

- Patients who received prior PI3K, AKT or mTOR inhibitors are not allowed

- Patients who received radiation therapy within the last 4 weeks; radiation exposure
may not exceed 30% of marrow area
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Joseph Kim

Role: Principal Investigator

Affiliation: Yale University Cancer Center LAO

Locations

Facility Status Contact
Los Angeles County-USC Medical Center
Los Angeles, California 90033
United States
Recruiting Site Public Contact
323-865-0451
USC / Norris Comprehensive Cancer Center
Los Angeles, California 90033
United States
Recruiting Site Public Contact
323-865-0451
Keck Medical Center of USC Pasadena
Pasadena, California 91105
United States
Recruiting Site Public Contact
323-865-0451
University of California Davis Comprehensive Cancer Center
Sacramento, California 95817
United States
Recruiting Site Public Contact
916-734-3089
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut 06510
United States
Recruiting Site Public Contact
203-785-5702
canceranswers@yale.edu
Yale University
New Haven, Connecticut 06520
United States
Recruiting Site Public Contact
203-785-5702
canceranswers@yale.edu
Northwestern University
Chicago, Illinois 60611
United States
Recruiting Site Public Contact
312-695-1301
cancer@northwestern.edu
University of Kansas Clinical Research Center
Fairway, Kansas 66205
United States
Recruiting Site Public Contact
913-945-7552
ctnursenav@kumc.edu
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland 21287
United States
Recruiting Site Public Contact
410-955-8804
jhcccro@jhmi.edu
Massachusetts General Hospital Cancer Center
Boston, Massachusetts 02114
United States
Recruiting Site Public Contact
877-726-5130
Brigham and Women's Hospital
Boston, Massachusetts 02115
United States
Recruiting Site Public Contact
888-823-5923
ctsucontact@westat.com
Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
United States
Recruiting Site Public Contact
617-667-9925
Dana-Farber Cancer Institute
Boston, Massachusetts 02215
United States
Recruiting Site Public Contact
877-442-3324
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan 48109
United States
Recruiting Site Public Contact
800-865-1125
Nebraska Medicine-Bellevue
Bellevue, Nebraska 68123
United States
Recruiting Site Public Contact
402-559-6941
unmcrsa@unmc.edu
Nebraska Medicine-Village Pointe
Omaha, Nebraska 68118
United States
Recruiting Site Public Contact
402-559-5600
University of Nebraska Medical Center
Omaha, Nebraska 68198
United States
Recruiting Site Public Contact
402-559-6941
unmcrsa@unmc.edu
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina 27599
United States
Recruiting Site Public Contact
877-668-0683
cancerclinicaltrials@med.unc.edu
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
United States
Recruiting Site Public Contact
412-647-8073
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
United States
Recruiting Site Public Contact
800-811-8480
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah 84112
United States
Recruiting Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu